0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Drug Discount Program

Sandra M. Swain, MD1; Jeffery C. Ward, MD2
[+] Author Affiliations
1Washington Cancer Institute, Medstar Washington Hospital Center, Washington, DC
2Medical Oncology, Swedish Cancer Institute Edmonds, Edmonds, Washington
JAMA. 2013;310(15):1626-1627. doi:10.1001/jama.2013.276737.
Text Size: A A A
Published online

Extract

To the Editor We believe that the Viewpoint by Drs Conti and Bach1 on the costs of the 340B drug discount program lacked a balanced perspective and perpetuated several misperceptions. The assertions made by the authors, particularly that physicians are altering prescribing behaviors to profit from 340B, have no factual underpinning.

We agree that the 340B program is poorly regulated and has reportedly been misused for competitive advantage in some communities, failing to serve its original purpose of incentivizing cancer care for the uninsured, underinsured, and Medicaid patients.2 This should not imply, however, that the program fails to serve eligible patients in most communities, and we applaud efforts under way to rein in any misuses of the program.3

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

October 16, 2013
Rena M. Conti, PhD
1Department of Pediatrics, University of Chicago, Chicago, Illinois
JAMA. 2013;310(15):1627. doi:10.1001/jama.2013.276770.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Collections
Jobs
brightcove.createExperiences();